WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Dr. Reddy’s Laboratories Ltd. - Growth / Value Index


RDY - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Excellent Score of 95.00
   Undervalued - Price to Intrinsic Value of 0.0011
   Price to Earning Ratio is 0.272 and EV to EBITDA is 0.335 suggesting company is undervalued.
   Price to Book Ratio is 0.0445 indicating that it is undervalued.
   Book Value in last 3 years is trending up
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 0.204 0.204 -18.76 %
Price to Book 0.0432 0.0406 -16.70 % 0.0406
Price to Sales 0.0407 0.0408 -11.60 %
Enterprise Value to EBITDA Multiple 0.253 0.226 -5.34 %


RDY - Profitability Highlights

Profitability Analysis

   Piotroski F Score - Excellent Value of 9.0
   Earning Yield of 367.25 %
   Company Earning excess return
   All key Trailing Twelve Months Margin growing by 15 %
   Annual Net Profit in last 3 years is trending up
   Steady Growth in EPS for last four quarters
   Good Return On Capital Employed of 18.39
   Good Return on Equity of 16.80% is achieved by the company
   Good Net Margin of 20.44% is achieved by the company
   Very Low Dividend Yield of 0.710 %
   EPS decline for last four quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 21.73 19.85 2.54 % 4.66
Return On Asset 15.77 14.37 2.93 % 3.37
Net Profit Margin 19.94 19.95 8.81 % 18.45
Operating Profit Margin 23.79 23.72 -31.68 % 20.88
EBITDA Margin 25.86 29.03 -4.07 % 26.12


Highlights
Market Cap11367.20 M
Enterprise Value18290.20 M
Price/Book TTM0.0432
Outstanding Share166528 K
Float/ Outstanding Share71.91%
Dividend Yield0.700 %
Share Holding
Guru Numbers
Price/Graham No0.0192
Peter Lynch Ratio113.14
Piotroski F Score5.00
Altman Z Score2.31
Sloan Ratio0.0265
Peter Lynch Fair Value5996.15


RDY - Growth Highlights

Growth Analysis

   Tsr Growth Index - Excellent Score of 90.56
   YoY Net Margin Jump by 66.75%
   Annual sales of the company is increased for three years in a row
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 279388 M 13.54 % 1.83 %
Gross Profit 172235 M 19.39 % 1.71 %
EBITDA 72254.00 M 8.91 % 13.09 %
Net Profit 55706.00 M 23.54 % 5.21 %
EPS 334.29 23.09 % NA


RDY - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 92.19
   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last five years
   Company financial liquidity has improved
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.050 -4.50 % 0.050
Cash Ratio 0.848 8.94 %
Quick Ratio 1.92 5.84 % 1.92
Shareholders Equity 72.40 0.375 %
Debt to EBITDA 0.173 5.64 %


Historical Valuation Ratios of Dr. Reddy’s Laboratories Ltd.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Dr. Reddy’s Laboratories Ltd.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Dr. Reddy’s Laboratories Ltd.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Dr. Reddy’s Laboratories Ltd.

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)